Business Context and Reporting Period
Company: Akers Biosciences, Inc. (Ticker: AKER)
Filing Type: Form 8-K (Current Report)
Date of Report: August 11, 2020
Reporting Period: Specific event date of August 11, 2020, regarding a registered direct offering.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than periodic financial performance. Key transaction metrics include:
- Shares Issued: 1,207,744 shares of Common Stock.
- Offering Price: $5.67 per share.
- Gross Proceeds: Approximately $6.8 million.
- Net Proceeds: Approximately $6.2 million (after fees and expenses).
- Placement Agent Fees: 7.5% cash fee plus 1.0% management fee of gross proceeds.
- Placement Agent Warrants: Warrants to purchase 96,620 shares at an exercise price of $7.0875, exercisable for five years.
- Other Expenses: $50,000 for non-accountable expenses and $12,900 for clearing expenses.
Note: The filing does not provide data on revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement for a registered direct offering. This transaction increases the company's share count and capital base. The closing of the offering was expected to occur on or about August 13, 2020, subject to customary closing conditions.
Outlook, Risks, and Management Commentary
- Use of Proceeds: The filing does not explicitly state the specific use of proceeds in the text provided, though such offerings typically fund operations and clinical development.
- Risks and Contingencies: The closing is contingent upon the satisfaction of conditions in the Purchase Agreement. The filing includes standard disclaimers that representations and warranties in the agreement are for risk allocation between parties and not necessarily statements of fact for investors.
- Unregistered Securities: Placement Agent Warrants and shares issuable upon exercise are unregistered, relying on Section 4(a)(2) and Regulation D exemptions.
Investor Verification Checklist
- Verify the final closing date of the offering (expected August 13, 2020).
- Confirm the exact number of shares issued and the final net proceeds received.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and conditions.
- Check subsequent filings for the actual use of the $6.2 million in net proceeds.
- Monitor the impact of the 1,207,744 new shares on existing shareholder dilution.